Drug intelligence / Profile preview

bromhexine (Sygen Pharmaceuticals Limited)

Development stage: Unknown
Lead developer: Sygen Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**Broncholyte** is an over-the-counter oral elixir marketed by Sygen Pharmaceuticals in Nigeria containing **bromhexine hydrochloride 4 mg/5 mL**. Bromhexine is a small-molecule mucolytic that reduces the viscosity of bronchial secretions, helping patients clear thick mucus through productive coughing. The registered product is indicated for cough and chest congestion, including respiratory conditions associated with abnormal mucus secretion such as chronic inflammatory pulmonary conditions, bronchitis with bronchospasm, and asthma. ([sygenpharma.com](https://www.sygenpharma.com/product/broncholyte-2/))

Brand names: Broncholyte

Beyond the preview

Go deeper on bromhexine (Sygen Pharmaceuticals Limited).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bromhexine (Sygen Pharmaceuticals Limited).

Explore the full profile